Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib Combined With Chidamide in Cutaneous T-Cell Lymphoma
NCT07754890Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in cutaneous T-cell lymphoma (CTCL), sponsored by Peking Union Medical College Hospital. Started Aug 2025; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07754890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754890.